Targeted Oncology2h
FDA OKs TLX007-CDx in Prostate Cancer Treatment
TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...
Nasdaq17d
Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug
The data showed that CDX-622 effectively neutralizes both targets, reducing tissue mast cells and Type 2 inflammatory responses, suggesting potential benefits over single-target therapies.
pharmaphorum7d
Study finds hundreds of overlooked cancer drug targets
That can throw out new targets for drug discovery, but also suggest ways in which existing drugs might be re-deployed to treat other forms of cancer – and hopefully help to improve on the ...
Business Insider17d
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
In the poster presented, preclinical studies demonstrate that CDX-622: About CDX-622 CDX-622 is a bispecific antibody that targets two complementary ... of Company drug candidates, including ...
Nasdaq23d
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
If approved, TLX250-CDx will become the first commercially available ... It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on 95% of ccRCC ...